CDAN1

Summary

Gene Symbol: CDAN1
Description: codanin 1
Alias: CDA1, CDAI, DLT, PRO1295, codanin-1, congenital dyserythropoietic anemia, type I, discs lost homolog
Species: human

Top Publications

  1. ncbi A phase I-II study of cyclophosphamide, epidoxorubicin, levofolinic acid/5-fluorouracil and recombinant human granulocyte colony stimulating factor in metastatic breast carcinoma
    A Callari
    Service of Chemotherapy, Oncological Hospital M. Ascoli, Palermo, Italy
    Acta Oncol 33:925-9. 1994
  2. ncbi Remote glucosyltransferase-microparticle vaccine delivery induces protective immunity in the oral cavity
    D J Smith
    Department of Immunology, The Forsyth Institute, Boston, MA 02115, USA
    Oral Microbiol Immunol 18:240-8. 2003
  3. pmc Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxorubicin-etoposide using granulocyte colony-stimulating factor with or without antimicrobial prophylaxis in patients with small-cell lung cancer
    A Ardizzoni
    Division of Medical Oncology I, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
    Br J Cancer 74:1141-7. 1996
  4. pmc The dlt operon of Bacillus cereus is required for resistance to cationic antimicrobial peptides and for virulence in insects
    Z Abi Khattar
    INRA, UMR 1133, Laboratoire EMIP, Place Eugene Bataillon, F 34095 Montpellier, France
    J Bacteriol 191:7063-73. 2009
  5. ncbi Total parenteral nutrition in treatment of patients with inflammatory bowel disease
    Kalina Grivceva Stardelova
    Gastroenterohepatology Clinic, Medical Faculty, Skopje, R Macedonia
    Prilozi 29:21-43. 2008
  6. ncbi Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group
    G Frasci
    Division of Medical Oncology A, National Tumor Institute, Naples, Italy
    Breast Cancer Res Treat 56:239-52. 1999
  7. ncbi Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma
    G C de Gast
    Division of Medical Oncology, Antoni van Leeuwenhoek Hospital Netherlands Cancer Institute, Amsterdam
    Clin Cancer Res 6:1267-72. 2000
  8. ncbi Toxicity of a quinocarmycin analog, DX-52-1, in rats and dogs in relation to clinical outcome
    Jon C Mirsalis
    Toxicology Laboratory, SRI International, 333 Ravenswood Avenue, Menlo Park, CA 94025 3493, USA
    Cancer Chemother Pharmacol 51:193-201. 2003
  9. doi Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study
    Pol Specenier
    Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium
    Anticancer Drugs 21:306-12. 2010
  10. ncbi Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer
    Antonius A Miller
    Comprehensive Cancer Center of Wake Forest University, Section on Hematology and Oncology, Medical Center Boulevard, Winston Salem, NC 27157, United States
    Lung Cancer 54:379-85. 2006

Detail Information

Publications132 found, 100 shown here

  1. ncbi A phase I-II study of cyclophosphamide, epidoxorubicin, levofolinic acid/5-fluorouracil and recombinant human granulocyte colony stimulating factor in metastatic breast carcinoma
    A Callari
    Service of Chemotherapy, Oncological Hospital M. Ascoli, Palermo, Italy
    Acta Oncol 33:925-9. 1994
    ..of the study, groups of 3 patients received EDXR 20, 25, 30, 35, and 40 mg/m2/day until the dose limiting toxicity (DLT) was reached...
  2. ncbi Remote glucosyltransferase-microparticle vaccine delivery induces protective immunity in the oral cavity
    D J Smith
    Department of Immunology, The Forsyth Institute, Boston, MA 02115, USA
    Oral Microbiol Immunol 18:240-8. 2003
    ..and 21 with a) GTF-MP alone, b) GTF-MP with cholera toxin, c) GTF-MP with detoxified mutant Escherichia coli toxin (dLT), or d) sham immunized with PLGA and cholera toxin...
  3. pmc Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxorubicin-etoposide using granulocyte colony-stimulating factor with or without antimicrobial prophylaxis in patients with small-cell lung cancer
    A Ardizzoni
    Division of Medical Oncology I, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
    Br J Cancer 74:1141-7. 1996
    ..3) completed three or more cycles at the dose and schedule planned by the protocol and no 'dose-limiting toxicity' (DLT) was seen...
  4. pmc The dlt operon of Bacillus cereus is required for resistance to cationic antimicrobial peptides and for virulence in insects
    Z Abi Khattar
    INRA, UMR 1133, Laboratoire EMIP, Place Eugene Bataillon, F 34095 Montpellier, France
    J Bacteriol 191:7063-73. 2009
    The dlt operon encodes proteins that alanylate teichoic acids, the major components of cell walls of gram-positive bacteria...
  5. ncbi Total parenteral nutrition in treatment of patients with inflammatory bowel disease
    Kalina Grivceva Stardelova
    Gastroenterohepatology Clinic, Medical Faculty, Skopje, R Macedonia
    Prilozi 29:21-43. 2008
    ..the course of the study, the following parameters were examined: Body mass index (BMI), Disease Activity Index (CDAI/AI), laboratory parameters and the number of hospital days...
  6. ncbi Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group
    G Frasci
    Division of Medical Oncology A, National Tumor Institute, Naples, Italy
    Breast Cancer Res Treat 56:239-52. 1999
    ..Weekly administration could result in a substantial improvement in the therapeutic index of cisplatin and paclitaxel. This study was aimed at determining the MTDs of epirubicin and paclitaxel given weekly with a fixed dose of cisplatin...
  7. ncbi Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma
    G C de Gast
    Division of Medical Oncology, Antoni van Leeuwenhoek Hospital Netherlands Cancer Institute, Amsterdam
    Clin Cancer Res 6:1267-72. 2000
    The purpose of our study was to determine the maximally tolerated dose (MTD) and DLT of combined administration of granulocyte macrophage colony-stimulating factor (GM-CSF), low-dose interleukin 2 (IL-2) and IFN-alpha in patients with ..
  8. ncbi Toxicity of a quinocarmycin analog, DX-52-1, in rats and dogs in relation to clinical outcome
    Jon C Mirsalis
    Toxicology Laboratory, SRI International, 333 Ravenswood Avenue, Menlo Park, CA 94025 3493, USA
    Cancer Chemother Pharmacol 51:193-201. 2003
    ..studies in rats and dogs to determine the maximum tolerated dose (MTD) and identify dose-limiting toxicities (DLT) in each species in different regimens to establish a safe starting dose and potential target organs of DX-52-1 for ..
  9. doi Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study
    Pol Specenier
    Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium
    Anticancer Drugs 21:306-12. 2010
    ..ifosfamide and cisplatin in patients with solid tumours and to define the safety, dose-limiting toxicity (DLT) and the recommended dose and administration schedule of docetaxel, ifosfamide and cisplatin for further phase II ..
  10. ncbi Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer
    Antonius A Miller
    Comprehensive Cancer Center of Wake Forest University, Section on Hematology and Oncology, Medical Center Boulevard, Winston Salem, NC 27157, United States
    Lung Cancer 54:379-85. 2006
    ..Follow-up was weekly for CBC. Tumor response was assessed after 2 and 6 cycles. Dose limiting toxicity (DLT) was defined as any of the following in cycle 1: grade 3 or 4 non-hematologic toxicity other than nausea and ..
  11. ncbi A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers
    P Bhargava
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Clin Cancer Res 7:3912-9. 2001
    ..in patients with advanced cancers to: (a) determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and pharmacokinetics of squalamine lactate when given as a 120-h continuous i.v...
  12. doi Choosing a lung isolation device for thoracic surgery: a randomized trial of three bronchial blockers versus double-lumen tubes
    Manu Narayanaswamy
    Gosford Hospital, Gosford, New South Wales 2250, Australia
    Anesth Analg 108:1097-101. 2009
    ..In this study, we compared the clinical performance of three bronchial blockers (BBs) available in North America with left-sided double-lumen tubes (DLTs) for lung isolation in patients undergoing left-sided thoracic surgery...
  13. ncbi Phase I study of docetaxel and topotecan in patients with solid tumors
    K H Tkaczuk
    University of Maryland Greenebaum Cancer Center, 22 South Greene St, Baltimore, MD 21201, USA
    Cancer Chemother Pharmacol 46:442-8. 2000
    ..This phase I trial was conducted to determine the overall and dose-limiting toxicities (DLT), the maximum tolerated dose (MTD) and the pharmacokinetics of the combination of DOC and TOPO in patients with ..
  14. ncbi Incorporation of D-alanine into lipoteichoic acid and wall teichoic acid in Bacillus subtilis. Identification of genes and regulation
    M Perego
    Dipartimento Farmaceutico, Facolta di Farmacia, Universita degli Studi di Parma, Italy
    J Biol Chem 270:15598-606. 1995
    The Bacillus subtilis dlt operon (D-alanyl-lipoteichoic acid) is responsible for D-alanine esterification of both lipoteichoic acid (LTA) and wall teichoic acid (WTA). The dlt operon contains five genes, dltA-dltE...
  15. pmc A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study
    R Glynne-Jones
    Mount Vernon Cancer Centre, Mount Vernon Hospital, Rickmansworth Road, Northwood, Middlesex HA6 2RN, UK
    Br J Cancer 96:551-8. 2007
    ..The MTD was determined as the dose causing more than a third of patients to have a dose-limiting toxicity (DLT) defined as specific grade 3 or 4 toxicities...
  16. pmc A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study
    D Sebag-Montefiore
    Cookridge Hospital, Hospital Lane, Cookridge, West Yorkshire LS16 6QB, UK
    Br J Cancer 93:993-8. 2005
    ..The MTD was determined as the dose causing more than a third of patients to have a dose-limiting toxicity (DLT). Once the MTD was reached, a further 14 patients were treated at the dose level below the MTD...
  17. ncbi Anti-interleukin-12 antibody for active Crohn's disease
    Peter J Mannon
    Mucosal Immunity Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 351:2069-79. 2004
    ..Crohn's disease is associated with excess cytokine activity mediated by type 1 helper T (Th1) cells. Interleukin-12 is a key cytokine that initiates Th1-mediated inflammatory responses...
  18. ncbi Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: results of a Phase I-II trial
    W Scheithauer
    Department of Internal Medicine I, Division of Oncology, University Medical School, Vienna, Austria
    Cancer 91:1264-71. 2001
    ..The aim of this disease oriented Phase I-II study was to determine the maximum tolerated dose (MTD), the dose-limiting toxicities (DLT), and the objective response rate of this combination in patients with advanced colorectal carcinoma.
  19. ncbi [Anesthesia in single and bilateral sequential lung transplantation. Lung Transplantation Group]
    G Della Rocca
    Istituto di Anestesia e Rianimazione, Universita degli Studi di Roma La Sapienza
    Minerva Anestesiol 66:183-93. 2000
    ..Anesthesia for lung transplantation: intraoperative complications and long term results...
  20. ncbi Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial
    Thomas Kuhnt
    Department of Radiotherapy, Martin Luther University, Halle, Germany
    Strahlenther Onkol 179:673-81. 2003
    ..combination protocol with cisplatin and escalated paclitaxel in combination with accelerated hyperfractionated radiotherapy to assess the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), overall toxicity, and response rate.
  21. ncbi Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors
    D Mavroudis
    Department of Medical Oncology, University General Hospital of Heraklion, Greece
    Oncology 62:216-22. 2002
    ..We conducted a phase I study to determine the maximum tolerated doses (MTD) and the dose limiting toxicities (DLT) of the combination administered every 2 weeks in patients with advanced solid tumors.
  22. ncbi Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study
    G L Phillips
    Blood and Marrow Transplant Program, University of Kentucky, Lexington, USA
    Biol Blood Marrow Transplant 10:473-83. 2004
    This study was conducted to define a new maximum tolerated dose and the dose-limiting toxicity (DLT) of melphalan and autologous hematopoietic stem cell transplantation (AHSCT) when used with the cytoprotective agent amifostine...
  23. ncbi Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas
    O S Nielsen
    Aarhus University Hospital, Department of Oncology, Norrebrogade 44, DK 8000 Aarhus C, Denmark
    Eur J Cancer 42:2303-9. 2006
    ..5 g; L4 and L5: X = 3 g. Cohorts of 3 patients were entered at each level unless a dose-limiting toxicity (DLT) occurred. In case of DLT in 1 of 3 patients a new cohort was added...
  24. pmc Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer
    Nicholas W Choong
    Section of Hematology Oncology, University of Chicago Medical Center, Chicago, IL 60615, USA
    J Thorac Oncol 3:59-67. 2008
    ....
  25. doi Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study
    Evangelos Briasoulis
    Department of Medical Oncology, Ioannina University Hospital, Greece
    Anticancer Drugs 21:785-9. 2010
    ..Patients with advanced cancer were eligible for this trial. Dose-limiting toxicity (DLT) was considered to be any grade greater than or equal to 3 (G> or =3) nonhematological toxicity except nausea/..
  26. ncbi [Therapeutic effects of combined enteral nutrition with Tripterygium Wilfordii poly-glycoside in remission induction of active adult Crohn's disease]
    Jian feng Gong
    Research Institute of General Surgery, Nanjing General Hospital of Nanjing Military Command, Nanjing 210002, China
    Zhonghua Wai Ke Za Zhi 47:1213-7. 2009
    ..To investigate the potential role of enteral nutrition (EN) combined with Tripterygium Wilfordii Poly-glycoside (TWP) for remission induction of active adult Crohn's disease (CD)...
  27. ncbi MR of the small bowel with a biphasic oral contrast agent (polyethylene glycol): technical aspects and findings in patients affected by Crohn's disease
    Andrea Laghi
    Dipartimento di Scienze Radiologiche, Universita degli Studi di Roma La Sapienza, Rome, Italy
    Radiol Med 106:18-27. 2003
    ..To report our experience using MR of the small bowel with polyethylene glycol (PEG) solution as an oral contrast agent in a population of adults and children with known Crohn's disease...
  28. ncbi Positioning of a double-lumen endobronchial tube without the aid of any instruments: an implication for emergency management
    J H Bahk
    Department of Anesthesiology and Clinical Research Institute, Seoul National University Hospital, Korea
    J Trauma 49:899-902. 2000
    ..If bleeding continues but the side of origin is uncertain, use of a double-lumen tube (DLT) is reasonable...
  29. ncbi Cloning, expression, and purification of cytidine deaminase from Arabidopsis thaliana
    S Vincenzetti
    Dipartimento di Scienze Morfologiche e Biochimiche Comparate, Universita di Camerino, Camerino MC, Italy
    Protein Expr Purif 15:8-15. 1999
    The complementary DNA (cDNA) coding for Arabidopsis thaliana cytidine deaminase 1 (AT-CDA1) was obtained from the amplified A. thaliana cDNA expression library, provided by R. W. Davis (Stanford University, CA)...
  30. doi Tolerance in DLA-haploidentical canine littermates following CD6-depleted marrow transplantation and donor lymphocyte transfusion
    Julia Zorn
    Helmholtz Zentrum Munchen, National Research Center for Environmental Health, Institute of Molecular Immunology, Clinical Cooperation Group Hematopoietic Cell Transplantation, Munich, Germany
    Exp Hematol 37:998-1006. 2009
    Donor lymphocyte transfusions (DLT) are effective in the treatment of leukemia after allogeneic stem cell transplantation. Graft-vs-host-disease (GVHD) is the major risk factor of DLT...
  31. pmc Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics
    D R Newell
    Medical School, University of Newcastle, UK
    Br J Cancer 81:760-8. 1999
    ..for 24 drugs, and in patients the maximum administered dose (MAD) was associated with dose-limiting toxicity (DLT) in initial clinical trials with 20 compounds...
  32. doi Prophylactic dexamethasone decreases the incidence of sore throat and hoarseness after tracheal extubation with a double-lumen endobronchial tube
    Sang Hyun Park
    Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, 300 Gumi dong, Seongnam City, Kyeonggi Do, 463 802, Korea
    Anesth Analg 107:1814-8. 2008
    ..are common complications after tracheal intubation, particularly after using a double-lumen endobronchial tube (DLT)...
  33. ncbi A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients
    M A Villalona-Calero
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, USA
    Ann Oncol 12:605-14. 2001
    ..The study also sought to recommend doses for subsequent disease-specific studies, identify clinically significant pharmacokinetic interactions, and detect preliminary antitumor activity...
  34. ncbi Bronchial blocker compared to double-lumen tube for one-lung ventilation during thoracoscopy
    C Bauer
    Anesthesiology Department, H pital Civil, Strasbourg University Hospital, France
    Acta Anaesthesiol Scand 45:250-4. 2001
    ..This study compared the Broncho-Cath double-lumen endotracheal tube with the Wiruthan bronchial blocker to determine the advantages of one device over the other during anaesthesia with one-lung ventilation for thoracoscopy...
  35. doi Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI
    Alain M Schoepfer
    Farncombe Family Institute of Digestive Health Research, McMaster University, Hamilton, Ontario, Canada
    Am J Gastroenterol 105:162-9. 2010
    ..The aim of this study was to evaluate the correlation between the SES-CD and fecal calprotectin, C-reactive protein (CRP), blood leukocytes, and the Crohn's disease activity index (CDAI).
  36. ncbi A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens
    Christos Kosmas
    Second Division of Medical Oncology, Department of Medicine, Metaxa Cancer Hospital, Piraues, 21 Apolloniou Street, 16341, Athens, Greece
    Cancer Chemother Pharmacol 59:51-9. 2007
    ..In the present phase I-II study, we evaluated the feasibility and efficacy of bi-weekly gemcitabine (GEM) + irinotecan (CPT-11) in patients with relapsed NSCLC...
  37. ncbi [Weekly paclitaxel with concurrent intensity-modulated radiotherapy for nasopharyngeal carcinoma: outcomes of a tolerance trial]
    Chun Yan Chen
    State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P R China
    Ai Zheng 26:398-402. 2007
    ..This study was to define the maximal tolerant dose (MTD) of paclitaxel in weekly paclitaxel with concurrent intensity-modulated radiotherapy (IMRT) for local-regionally advanced NPC...
  38. ncbi Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG)
    F Caponigro
    Medical Oncology A, National Tumor Institute G Pascale, Napoli, Italy
    Ann Oncol 11:575-80. 2000
    ..Preclinical data support the combination of CDDP and raltitrexed. The aim of the present study was to evaluate the combination of cisplatin, raltitrexed. LFA and 5-FU in a phase I-II study...
  39. ncbi Escalating doses of paclitaxel and epirubicin in combination with cisplatin in advanced ovarian epithelial carcinoma: a phase I-II study
    Vittorio Gebbia
    Department of Experimental Oncology, University of Palermo, Italy
    Anticancer Drugs 14:359-64. 2003
    ..A phase I study was carried out to evaluate the dose-limiting toxicity (DLT) and the maximally tolerated dose (MTD) of PXT and EPI in combination with a fixed dose of cisplatin every 4 weeks...
  40. doi Dose escalation study of epirubicin and docetaxel in patients with advanced or recurrent breast cancer
    Ichiro Ichinose
    Department of Medicine, Fukuoka University School of Medicine, Fukuoka, Japan
    Chemotherapy 54:379-85. 2008
    ..To develop a combination of epirubicin (EPI) and docetaxel (DTX) in Japan, dose escalation and pharmacokinetic studies were performed in patients with advanced or recurrent breast cancer...
  41. ncbi Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group
    K Ewe
    I Medizinische Klinik und Poliklinik, Johannes Gutenberg Universitat Mainz, Germany
    Eur J Gastroenterol Hepatol 11:277-82. 1999
    ..Endoscopic recurrence of Crohn's disease frequently occurs within weeks after 'curative' operation. Treatment with 3 x 1 mg oral pH-modified release budesonide was tried to prevent postoperative recurrence...
  42. ncbi Inflation of the distal cuff by saline reduces the incidence of malposition of the bronchial tube during lung separation in patients receiving nitrous oxide
    Manzo Suzuki
    Department of Anesthesiology, Second Hospital Nippon Medical School, Kanagawa, Japan
    J Cardiothorac Vasc Anesth 21:838-42. 2007
    A common problem during lung separation is malposition of the double-lumen tube (DLT). It was hypothesized that inflation of the distal cuff with saline instead of air may reduce the incidence of malposition of the endobronchial tube.
  43. ncbi Azathioprine as a postoperative prophylaxis reduces symptoms in aggressive Crohn's disease
    Pär Myrelid
    Department of Surgery, Unit of Colorectal Surgery, Linkoping University Hospital, Sweden
    Scand J Gastroenterol 41:1190-5. 2006
    ..This study comprises a subset of CD patients considered to have an aggressive disease course and chosen for treatment with Aza postoperatively...
  44. doi Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI)
    Brett A Leav
    MassBiologics, University of Massachusetts Medical School, Boston, MA, USA
    Vaccine 28:965-9. 2010
    ..Previous studies have demonstrated a correlation between Clostridium difficile anti-toxin A serum antibodies and protection against symptomatic disease and recurrence...
  45. ncbi Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease
    Siew C Ng
    St Mark s Hospital, Harrow, UK
    Inflamm Bowel Dis 13:129-34. 2007
    ..This study aimed to evaluate the efficacy of oral tacrolimus in patients with inflammatory bowel disease (IBD) refractory to conventional therapy, including azathioprine, 6-mercaptopurine, and infliximab...
  46. ncbi Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group
    P Comella
    Division of Medical Oncology A, National Tumour Institute, Naples, Italy
    Oncology 60:127-33. 2001
    ....
  47. doi Age, dose, and time-dependency of plasma and tissue distribution of deltamethrin in immature rats
    Kyu Bong Kim
    Department of Pharmaceutical Engineering, Inje University, Gimhae, Gyongam 621 749, Korea
    Toxicol Sci 115:354-68. 2010
    The major objective of this project was to characterize the systemic disposition of the pyrethroid, deltamethrin (DLT), in immature rats, with emphasis on the age dependence of target organ (brain) dosimetry...
  48. ncbi Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease
    B E Sands
    Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Boston, 02114, USA
    Aliment Pharmacol Ther 16:399-406. 2002
    ..Interleukin-11 is a mesenchymally derived cytokine with pleiotropic activities. A pilot study suggested therapeutic benefit of recombinant human interleukin-11 (rhIL-11) in patients with Crohn's disease...
  49. ncbi Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings
    Taina Sipponen
    Department of Medicine, Division of Gastroenterology, Helsinki University Central Hospital, Helsinki, Finland
    Inflamm Bowel Dis 14:40-6. 2008
    ..We evaluated the clinical significance of these neutrofil-derived proteins in assessment of Crohn's disease activity by comparing them with endoscopic disease activity and with Crohn's disease activity index (CDAI) and serum CRP.
  50. doi Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn's disease - A controlled clinical trial
    Simone Krebs
    Department of Nuclear Medicine, Faculty of Medicine, University of Freiburg, Germany
    Phytomedicine 17:305-9. 2010
    ..Minimum score of 200 on Crohn's Disease Activity Index (CDAI) was required at baseline for inclusion in each group...
  51. ncbi Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Intern Med 146:829-38. 2007
    ..No anti-TNF agent has been evaluated prospectively in patients with Crohn disease who had responded to another anti-TNF agent and then lost that response or were intolerant of the agent...
  52. doi A novel toxicity scoring system treating toxicity response as a quasi-continuous variable in Phase I clinical trials
    Zhengjia Chen
    Rollins School of Public Health, Emory University, Atlanta, GA 30322, United States
    Contemp Clin Trials 31:473-82. 2010
    ..all current Phase I designs, toxicity response is treated coarsely as a binary indicator of dose limiting toxicity (DLT) and a lot of useful toxicity information is discarded...
  53. ncbi Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma
    David N Korones
    James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Cancer 97:1963-8. 2003
    ..Temozolomide may prove more effective in combination with other agents. Therefore, combination oral chemotherapy for these patients is a particularly attractive approach...
  54. pmc Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial
    T Ernst
    Onkologisches Zentrum, III Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Theodor Kutzer Ufer 1 3, Mannheim 68167, Germany
    Br J Cancer 97:1475-9. 2007
    ..Cycles were repeated every 3 weeks. The primary aim was to determine the dose-limiting toxicities (DLT) during the first two treatment cycles and the maximum tolerated dose (MTD)...
  55. ncbi Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group
    P Schoffski
    Department of Haematology and Oncology, Hannover Medical School, Hannover, Germany
    Ann Oncol 15:1816-24. 2004
    ..The current study was performed to determine the safety profile, dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of the intravenous (i.v.) administration of aviscumine in cancer patients...
  56. pmc Genetic deletion of cell division autoantigen 1 retards diabetes-associated renal injury
    Zhonglin Chai
    Proliferation and Fibrosis Laboratory and
    J Am Soc Nephrol 24:1782-92. 2013
    Cell division autoantigen 1 (CDA1) enhances TGF-β signaling in renal and vascular cells, and renal expression of CDA1 is elevated in animal models of diabetes...
  57. ncbi The role of the dorsolateral tegmentum in the control of male sexual behavior: a reevaluation
    J C Romero-Carbente
    Instituto de Neurobiologia, Universidad Nacional Autonoma de Mexico, Apartado Postal 1 1141, Queretaro, Qro 76230, Mexico
    Behav Brain Res 170:262-70. 2006
    ..The MPOA/AH projects among other structures to the dorsolateral tegmentum (DLT)...
  58. pmc A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: first report of the Children's Cancer Group-0952
    Seema N Sanghavi
    Department of Human Oncology, Medical School, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA
    Neuro Oncol 5:8-13. 2003
    ..4 Gy. Dose escalation of topotecan was carried out using a standard phase I design. Dose limiting toxicity (DLT) was defined as an absolute neutrophil count (ANC) of < or =500/mm(3) for > or =7 days; platelets of < or =50,..
  59. ncbi Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer
    Faye M Johnson
    Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, USA
    Clin Lung Cancer 5:40-5. 2003
    ..Patients received 12 weeks of therapy. To evaluate dose escalation in subsequent cohorts, dose-limiting toxicity (DLT) was initially assessed during weeks 1-3 of treatment...
  60. ncbi A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targeting
    Sanjeev Sewak
    New York University School of Medicine Kaplan Comprehensive Cancer Center, NY 10016, USA
    Anticancer Drugs 14:67-72. 2003
    ..This study was designed to define the dose-limiting toxicity (DLT) and recommended phase II dose (RPTD) of the unique triplet combination of paclitaxel, estramustine phosphate (EMP) ..
  61. ncbi Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Saitama, Japan
    Anticancer Res 22:1833-8. 2002
    ..Three new patients were to be entered at escalation doses unless dose-limiting toxicities (DLT) occurred, defined as grade 4 hematological or grade 3/4 non-hematological toxicities...
  62. doi Stem cells as treatment in inflammatory bowel disease
    C J Hawkey
    Nottingham Digestive Diseases Centre, Nottingham, UK cj hawkey nottingham ac uk
    Dig Dis 30:134-9. 2012
    ..Recruitment of all 48 patients in the trial will be completed in early 2012 and the results to date are descriptively presented here...
  63. doi Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure
    Hiroki Wakabayashi
    Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, 2 174 Edobashi, Tsu, Mie 514 8507, Japan
    Clin Rheumatol 32:253-9. 2013
    ..Protein (DAS28-CRP), the Simplified Disease Activity Index (SDAI), and the Clinical Disease Activity Index (CDAI)...
  64. pmc The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials
    Alexia Iasonos
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Cancer Res 18:5179-87. 2012
    The rate of observed dose-limiting toxicities (DLT) determines the maximum tolerated dose (MTD) in phase I trials...
  65. pmc DWARF AND LOW-TILLERING acts as a direct downstream target of a GSK3/SHAGGY-like kinase to mediate brassinosteroid responses in rice
    Hongning Tong
    State Key Laboratory of Plant Genomics and National Center for Plant Gene Research Beijing, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China
    Plant Cell 24:2562-77. 2012
    ..DWARF AND LOW-TILLERING (DLT) is a positive regulator that mediates several BR responses in rice...
  66. pmc Codanin-1, mutated in the anaemic disease CDAI, regulates Asf1 function in S-phase histone supply
    Katrine Ask
    Biotech Research and Innovation Centre BRIC, University of Copenhagen, Copenhagen, Denmark
    EMBO J 31:2013-23. 2012
    ..Mutations in Codanin-1 can cause congenital dyserythropoietic anaemia type I (CDAI), characterized by chromatin abnormalities in bone marrow erythroblasts. Codanin-1 is part of a cytosolic Asf1-H3...
  67. pmc Regulated expression of the Streptococcus mutans dlt genes correlates with intracellular polysaccharide accumulation
    G A Spatafora
    Department of Biology, Middlebury College, Middlebury, Vermont 05753, USA
    J Bacteriol 181:2363-72. 1999
    ..We therefore assigned a new dlt designation to the locus which we had formerly called glg. We maintain that the dlt genes are involved in S...
  68. ncbi [Effects of selective left lower lobar blockade by Coopdech endobronchial blocker tube on intrapulmonary shunt and arterial oxygenation: a comparison with double-lumen endobronchial tube]
    Jing Ye
    Department of Anesthesiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
    Nan Fang Yi Ke Da Xue Xue Bao 29:2244-7. 2009
    ..arterial oxygenation between selective left lower lobar blockade by Coopdech endobronchial blocker tubes (BB) and one lung ventilation (OLV) by left-sided double-lumen endobronchial tubes (DLT) in patients with normal pulmonary function.
  69. ncbi Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society
    G Hartung
    Oncology Center, III, Medical University Clinic Mannheim, Germany
    Clin Cancer Res 5:753-9. 1999
    ..The objectives of this first Phase I study of MTX-HSA were to determine dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) in a weekly regimen...
  70. doi Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level
    Keiko Funahashi
    Department of Clinical Research, Matsubara Mayflower Hospital, 944 25 Fujita, Kato, Hyogo, 673 1462, Japan
    Mod Rheumatol 19:507-12. 2009
    ..In order to evaluate the effects of tocilizumab we carried out this study using clinical disease activity index (CDAI), as it is not reliant on blood data and would also allow us to determine which markers are present in remission...
  71. ncbi Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer: a phase I study
    C Gridelli
    Divisione di Oncologia Medica B, Istituto Nazionale Tumori, Naples, Italy
    Lung Cancer 29:131-7. 2000
    ..The first dose of vinorelbine was 4 mg/m(2) and it showed to be feasible without dose-limiting toxicity (DLT)...
  72. ncbi Quality of life in Korean patients with inflammatory bowel diseases: ulcerative colitis, Crohn's disease and intestinal Behçet's disease
    W H Kim
    Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seodaemun Ku, Seoul, Korea
    Int J Colorectal Dis 14:52-7. 1999
    ..Disease activity was measured by St. Mark's Activity Index, Crohn's disease Activity Index (CDAI), and the Harvey-Bradshaw Index (HBI)...
  73. doi Contrast-enhanced ultrasonographic evaluation of inflammatory activity in Crohn's disease
    Vincenzo Migaleddu
    Sardinian Mediterranean Imaging Research Group, Sassari, Italy
    Gastroenterology 137:43-52. 2009
    ..US (CE-US) in the evaluation of inflammatory activity in patients with Crohn's disease (CD), and to correlate the findings of these sonographic studies with inflammatory activity, as scored by the CD activity index (CDAI).
  74. doi The rheumatoid arthritis disease activity index-5 in daily use. Proposal for disease activity categories
    Bernhard Rintelen
    1st and 2nd Department of Medicine, Center for Rheumatology, Lower Austrian State Hospital, Stockerau, Austria
    J Rheumatol 36:918-24. 2009
    ..To establish thresholds for rheumatoid arthritis (RA) activity categories according to the RA Disease Activity Index-5 (RADAI-5)...
  75. ncbi SET-related cell division autoantigen-1 (CDA1) arrests cell growth
    Z Chai
    Department of Pathology and Immunology, Monash University Medical School, Prahran, Victoria 3181, Australia
    J Biol Chem 276:33665-74. 2001
    ..Its open reading frame of 2079 base pairs encodes a predicted polypeptide of 693 amino acids named CDA1 (cell division autoantigen-1). CDA1 has a predicted molecular mass of 79,430 Daltons and a pI of 4.26...
  76. ncbi An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer
    H Bonnefoi
    Hĵpitaux Universitaires de Genève, Geneve, Switzerland
    Breast Cancer Res Treat 70:55-63. 2001
    ....
  77. doi A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Clin Cancer Res 14:6310-6. 2008
    ..To determine the maximally tolerated dose (MTD) of biweekly pemetrexed with gemcitabine plus B(12) and folate supplementation in patients with advanced solid tumors and ovarian cancer...
  78. doi Incidence, management and clinical outcomes of patients with airway complications following lung transplantation
    Paula Moreno
    Department of Thoracic Surgery and Lung Transplantation Unit, University Hospital Reina Sofia, Cordoba, Spain
    Eur J Cardiothorac Surg 34:1198-205. 2008
    ..Airway complications (AC) remain a significant contributing factor of morbidity after lung transplantation (LT). The aim of this study was to identify risk factors for AC, and to review the outcomes after endoscopic and surgical treatment...
  79. ncbi Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors
    K A Gelmon
    British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, British Columbia, Canada
    J Clin Oncol 18:4098-108. 2000
    To define the maximum-tolerated dose, recommended phase II dose (RD), dose-limiting toxicity (DLT), and pharmacokinetics of a novel taxane, RPR 109881A, administered on days 1 and 8 of a 21-day cycle.
  80. ncbi Predicting the size of a double-lumen endobronchial tube based on tracheal diameter
    M Y Chow
    Department of Anesthesia, Tan Tock Seng Hospital, Singapore
    Anesth Analg 87:158-60. 1998
    ..whether using the tracheal diameter to predict the correct size of the left double-lumen endobronchial tube (DLT) could be used for our generally smaller sized Asian patients...
  81. doi Associations between the American College of Rheumatology pediatric response measures and the continuous measures of disease activity used in adult rheumatoid arthritis: a secondary analysis of clinical trial data from children with polyarticular-course j
    Sarah Ringold
    Seattle Children s Hospital and Regional Medical Center, and University of Washington, Seattle, WA 98105, USA
    Arthritis Rheum 60:3776-83. 2009
    ....
  82. doi Regulation of D-alanylation of lipoteichoic acid in Streptococcus gordonii
    Nicole E McCormick
    Department of Microbiology and Immunology, Dalhousie University and the IWK Health Center, Halifax, NS, Canada
    Microbiology 157:2248-56. 2011
    ..In this study, expression of the dlt operon responsible for d-alanylation of LTA was examined in the commensal bacterium Streptococcus gordonii...
  83. doi A wide-spectrum paired comparison of the properties of the Rolling 6 and 3+3 Phase I study designs
    Richard Sposto
    Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California 90027 6016, USA
    Contemp Clin Trials 32:694-703. 2011
    ..trial by reducing the downtime during which Phase I trials are suspended for evaluation of dose-limiting toxicity (DLT)...
  84. doi Codanin-1 mutations in congenital dyserythropoietic anemia type 1 affect HP1{alpha} localization in erythroblasts
    Raffaele Renella
    Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK
    Blood 117:6928-38. 2011
    ..Mice containing a gene-trapped Cdan1 locus demonstrate its widespread expression during development...
  85. doi Cell division autoantigen 1 enhances signaling and the profibrotic effects of transforming growth factor-β in diabetic nephropathy
    Yugang Tu
    Diabetes and Metabolism Division, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia
    Kidney Int 79:199-209. 2011
    Cell division autoantigen 1 (CDA1) modulates cell proliferation and transforming growth factor-β (TGF-β) signaling in a number of cellular systems; here we found that its levels were elevated in the kidneys of two animal models of ..
  86. doi Identification and characterization of dwarf 62, a loss-of-function mutation in DLT/OsGRAS-32 affecting gibberellin metabolism in rice
    Wenqiang Li
    Department of Agronomy, College of Agriculture and Biotechnology, Zhejiang University, Hangzhou, 310029, China
    Planta 232:1383-96. 2010
    ..Positional cloning of D62 gene revealed that it was the same locus as DLT/OsGRAS-32, which encodes a member of the GRAS family...
  87. ncbi Lung mechanics and dyspnea after lung transplantation for chronic airflow obstruction
    F J Martinez
    Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, USA
    Am J Respir Crit Care Med 153:1536-43. 1996
    ..lung volume (EELV) and result in a different respiratory sensation compared with double lung transplantation (DLT). Eight SLT recipients and 12 DLT recipients demonstrated a similar maximal work load and achieved VO2...
  88. pmc Minimal access mediastinal surgery: One or two lung ventilation?
    Karamollah Toolabi
    Department of Surgery, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
    J Minim Access Surg 5:103-7. 2009
    Minimal access mediastinal surgery (MAMS) is usually performed under general anaesthesia with double lumen tubes (DLT)...
  89. doi Mapping and validation of simple sequence repeat markers linked to a major gene controlling seed cadmium accumulation in soybean [Glycine max (L.) Merr]
    Souframanien Jegadeesan
    Greenhouse and Processing Crops Research Centre, Agriculture and Agri Food Canada, 2585 County Road 20, Harrow, Ontario, Canada
    Theor Appl Genet 121:283-94. 2010
    ..high and an F(2:3) population showed that low Cd accumulation in soybean seed is under the control of a major gene (Cda1, proposed name) with the allele for low accumulation being dominant...
  90. pmc Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide
    V M Herben
    Department of Medical Oncology, Antoni van Leeuwenhoek Hospital Netherlands Cancer Institute, Amsterdam
    Br J Cancer 76:1500-8. 1997
    ..a phase I and pharmacological study to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of a cytotoxic regimen of the novel topoisomerase I inhibitor topotecan in combination with the topoisomerase II ..
  91. ncbi A phase I study of paclitaxel, cisplatin, and fluorouracil (TCF) for advanced gastric cancer
    Takuo Hara
    Department of Surgery, Kouseiren Takaoka Hospital, Takaoka, Toyama 933 8555, Japan
    Cancer Chemother Pharmacol 59:631-6. 2007
    ..in advanced gastric cancer patients was performed to determine the recommended dose (RD) for a phase II study by checking the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of 5-FU above the fixed dose of TXL and CDDP.
  92. doi A phase I study of S-1 treatment with a 3 week schedule in advanced biliary cancer patients with or without hepatic dysfunction
    Dok Hyun Yoon
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Songpa Gu, Seoul, 138 736, Korea
    Invest New Drugs 29:332-9. 2011
    ..Hepatic dysfunction (HD) is common in patients with biliary tract cancer. A phase I study was conducted to assess the effects of a 3 week treatment schedule in Asian patients with or without HD...
  93. doi RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care
    Theodore Pincus
    Division of Rheumatology, Department of Medicine, New York University School of Medicine and NYU Hospital for Joint Diseases, Room 1608, 301 East 17th Street, New York, NY 10003, USA
    Rheum Dis Clin North Am 35:773-8, viii. 2009
    ..RAPID3 scores are correlated with the disease activity score 28 (DAS28) and clinical disease activity index (CDAI) in clinical trials and clinical care, and are comparable to these indices in capacity to distinguish active from ..
  94. doi Data from eye-tracking corpora as evidence for theories of syntactic processing complexity
    Vera Demberg
    School of Informatics, University of Edinburgh, Edinburgh, UK
    Cognition 109:193-210. 2008
    We evaluate the predictions of two theories of syntactic processing complexity, dependency locality theory (DLT) and surprisal, against the Dundee Corpus, which contains the eye-tracking record of 10 participants reading 51,000 words of ..
  95. ncbi Twenty-four-hour energy balance in Crohn disease patients: metabolic implications of steroid treatment
    G Mingrone
    Istituto di Medicina Interna, Universita Cattolica del Sacro Cuore, Rome, Italy
    Am J Clin Nutr 67:118-23. 1998
    ..Five patients [Crohn's disease activity index (CDAI) = 98.4 +/- 3.78] took no medication and seven patients (CDAI = 283.9 +/- 22...
  96. pmc A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma
    Tom Budiharto
    Department of Radiotherapy, University Hospitals Leuven, Leuven, Belgium
    Radiat Oncol 3:30. 2008
    ..The primary objective of this study was to determine the maximum tolerated dose (MTD) of escalating doses of radiotherapy (RT) concomitantly with a fixed dose of gemcitabine (300 mg/m2/week) within the same overall treatment time...
  97. ncbi RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories
    Theodore Pincus
    New York University Hospital for Joint Diseases, New York, New York 10003, USA
    J Rheumatol 35:2136-47. 2008
    ..Patient Index Data 3), an index without formal joint counts, which is scored in < 10 seconds to 4 categories of the Disease Activity Score (DAS28) and Clinical Disease Activity Index (CDAI) in patients with rheumatoid arthritis (RA).
  98. ncbi Modified right-sided Broncho-Cath double lumen tube improves endobronchial positioning: a randomized study
    Jean S Bussieres
    Department of Anesthesiology, Laval University Heart and Lung Institute, Laval Hospital, 2725, Chemin Ste Foy, Ste Foy, Quebec G1V 4G5, Canada
    Can J Anaesth 54:276-82. 2007
    ..one-lung ventilation for most thoracic surgeries, but for certain indications, a right-sided double lumen tube (R-DLT) may be mandatory. Frequent malposition of R-DLTs has been reported...
  99. ncbi Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients
    Mario Campone
    Centre Rene Gauducheau, Nantes, France
    Cancer Chemother Pharmacol 60:523-33. 2007
    ..To determine the maximum tolerated dose (MTD) safety and pharmacokinetics of AP5346, a copolymer-linked 1,2-diaminocyclohexane(DACH)-platinum compound, in advanced solid tumor patients...
  100. ncbi Phase I trial of perillyl alcohol administered four times daily continuously
    Sherry Morgan-Meadows
    University of Wisconsin Comprehensive Cancer Center, 600 Highland Ave K4 601, Madison, Wisconsin 53792, USA
    Cancer Chemother Pharmacol 52:361-6. 2003
    ..Dose-limiting toxicities (DLT) were primarily gastrointestinal...
  101. ncbi A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitor
    Amin M Alousi
    Karmanos Cancer Institute, Wayne State University School of Medicine, 4th Floor HWCRC, 4100 John R, Detroit, MI 48201, USA
    Invest New Drugs 25:147-54. 2007
    ..Based on encouraging pre-clinical data, a phase I trial was conducted to determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD).

Research Grants78

  1. Fatty Acid Synthase Inhibitors: Ovarian Cancer Therapy
    ALBERT OWENS; Fiscal Year: 2007
    ..cell line OVCAR-3; 3) a determination of the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) in BALB/C mice on low and high fat diets; and, 4) efficacy studies using OVCAR-3 xenografts grown in athymic BALB/..
  2. Vaccination With Peptide-loaded alphaDC1s For Malignant Gliomas
    Hideho Okada; Fiscal Year: 2007
    ..single-institutional trial designed to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT), and to evaluate the induction of an immune and clinical response (secondary objectives) of glioma associated ..
  3. Lapatinib in childhood CNS malignancies
    Maryam Fouladi; Fiscal Year: 2006
    ..The primary aims of this proposal are a) to determine the maximum tolerated dose (MTD), dose limiting toxicities (DLT) and pharmacokinetics (PK) of Lapatinib in children with recurrent CNS malignancies in a phase I study; b) to ..
  4. A Phase I Study of Single Agent Flavopiridol in B-Cell *
    Thomas Lin; Fiscal Year: 2007
    ..using this dosing schedule in patients with relapsed B-NHL, in order to determine the dose limiting toxicity (DLT), maximum tolerated dose (MTD) and toxicity profile of this dosing schedule in 1) indolent B-NHL, 2) MCL, and 3) ..
  5. Hsp90 as a Target for the Treatment of Childhood Cancer
    Rochelle Bagatell; Fiscal Year: 2007
    ..Primary objectives of the trial will be to establish the Dose Limiting Toxicity (DLT) and the Maximum Tolerated Dose (MTD) of 17-DMAG in these patients and to assess the extent to which the MTD of ..
  6. Phase I study of 8-Cl-adenosine in CLL (IND 68,229)
    Varsha Gandhi; Fiscal Year: 2009
    ..in subjects with CLL to determine the hematological and nonhematological toxicity profile and identify the MTD and DLT. Aim 2. Using established guidelines evaluate efficacy of 8-Cl-Ado...
  7. Molecular Correlates--Oxaliplatin/5FU/XRT, Esophageal CA
    Lakshmi Pendyala; Fiscal Year: 2002
    ..between PK and changes in intratumoral gene expression and 4) maximum tolerated dose (MTD), dose limiting toxicity (DLT), and the potential therapeutic responses to OXP when given with continuous infusion 5FU + XRT...
  8. Immunotoxin-Induced Vascular Leak Syndrome
    Ellen Vitetta; Fiscal Year: 2005
    ..The response rate has been 40% and the dose limiting toxicity (DLT) has been vascular leak syndrome (VLS)...
  9. Phase ii intraperitoneal rhIL 12
    Ralph Freedman; Fiscal Year: 2002
    ..We have determined the dose limiting toxicity (DLT) of IP rhIL-12 (Genetics Institute) in a phase I clinical trial in a once weekly IP injection schedule...
  10. Innate immune defense against community associated methicillin-resistant S.aureus
    WILLIAM NAUSEEF; Fiscal Year: 2009
    ..Our data demonstrate that the increased resistance of CA- MRSA to GpIIA-PLA2 requires expression of the dlt operon, a critical determinant of cell wall synthesis...
  11. Innate immune defense against community associated methicillin-resistant S.aureus
    William Michael Nauseef; Fiscal Year: 2010
    ..Our data demonstrate that the increased resistance of CA- MRSA to GpIIA-PLA2 requires expression of the dlt operon, a critical determinant of cell wall synthesis...
  12. Effects of naltrexone on active Crohn's disease
    Jill Smith; Fiscal Year: 2007
    ..in subjects with active Crohn's disease and found significant improvement in the Crohn's Disease Activity Index (CDAI) as well as endoscopic reversal of inflammation...
  13. DEVELOPMENT OF POLY-L-GLUTAMIC ACID PACLITAXEL CONJUGATE
    Sidney Wallace; Fiscal Year: 2005
    ..This study will determine MTD, DLT, pharmacokinetics, assess toxicity, and document patient costs...
  14. NEUREXIN IV, GROWTH CONTROL, AND CANCER
    Manzoor Bhat; Fiscal Year: 2002
    ..Mutational analysis of the gene encoding this protein, discs lost (dlt), suggest that it may also play a role in the control of cell proliferation: in the absence of DLT protein, ..
  15. Phase I and Biological Studies of DB67 - A Blood Stable Camptothecin
    Markos Leggas; Fiscal Year: 2007
    ..1) To estimate the maximum tolerated dose (MTD) and describe the dose limiting toxicities (DLT) of intravenous DB-67 administered once daily for 5 days every 21 days to adults with recurrent or refractory solid ..
  16. A Conceputal and Empirical Analysis of Cost Analysis
    Aaron Beaston Blaakman; Fiscal Year: 2004
    ..an empirical reliability study of a brief, telephone-based, cost analysis instrument (Cost Data Audit Instrument, CDAI) used in the Alcohol and Drug Services Study (ADSS)...